{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Biopsy testes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Computerized tomogram"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Nuclear magnetic resonance imaging"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Ultrasound testes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Open reduction of fracture"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Orchidectomy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"208"}],"units":"Participants"}],"description":"Procedures will be coded using the same version of MedDRA as for medical history. Medical procedures will be displayed as a listing by participant.","groups":[{"description":"Participants with suspected recurrence of prostate cancer and negative or equivocal findings per institutional standard of care conventional imaging were enrolled to receive a single dose of 9 mCi (333 MBq) 18F-DCFPyL injection followed by a single PET/CT scan acquired 1 to 2 hours post-dosing.","id":"OG000","title":"18F-DCFPyL Injection"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety Set includes all participants who received any amount of 18F-DCFPyL.","reportingStatus":"POSTED","timeFrame":"From the time of 18F-DCFPyL dosing to completion of the follow-up visit at 7 (±3) days after 18F-DCFPyL dosing.","title":"Collection of Medical Procedures (Safety Outcome Measure)","type":"SECONDARY","unitOfMeasure":"Participants"}